Summary
This study describes a comparison of 1-p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt (DM-COOK) and imidazole-4-carboxamide,5-(3,3-dimethyl-1-triazeno) (DTIC) with reference to antitumor activity on different murine tumors and hematological toxicity. DM-COOK appeared comparably or slightly more effective in L1210, P388, and M5 tumors in the mouse. However, when the treatment of mice bearing M5 with DM-COOK was combined with surgical removal of the primary tumor, the host's life-span was highly significantly prolonged. The two drugs showed similar activity in an M5 variant selected for resistance to cyclophosphamide. In L1210 Ha, a leukemia that is spontaneously resistant to DTIC, DM-COOK was not effective.
Both DM-COOK and DTIC caused transient leukopenia with a maximum WBC fall of 57% and 71% compared with control values. DM-COOK's greater chemical stability might be an advantage, as the decomposition of DTIC is thought to lead to products responsible for some toxic effects in humans. Like other phenyldimethyltriazenes DM-COOK, is a good candidate for clinical trials because its water solubility eliminates formulation problems.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Audette Stanley RC, Connors TA, Mandel HG, Merai K, Ross WCJ (1973) Studies on the mechanisms of action of the tumour-inhibitory triazenes. Biochem Pharmacol 22:1855
Bonmassar E, Nicolin A, Spreafico F (1979) Drug-induced modifications of tumor-cell antigenicity. In: Spreafico F, Arnon R (eds) Tumor-associated antigens and their specific immune response. Academic Press, New York, p 251
Colombo T, Garattini S, Lassiani L, D'Incalci M (1982) Activity of 1-p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt in M 5076/73A ovarian reticular cell sarcoma of the mouse. Cancer Treat Rep 66:1945
Connors TA, Goddard PM, Merai PM, Merai K, Ross WCJ, Wilman DEV (1976) Tumor inhibitory triazenes: Structural requirements for an active metabolite. Biochem Pharmacol 25:241
D'Incalci M, Torti L, Damia G, Erba E, Morasca L, Garattini S (1983) An ovarian reticular cell sarcoma of the mouse (M 5076) made resistant to cyclophosphamide: A new model. Cancer Res 43:5674
Geran RI, Greenberg NH, Macdonald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems, 3rd ed. Cancer Chemother Rep [3]3:1
Giraldi T, Sava G, Cuman R, Nisi C, Lassiani L (1981) Selectivity of the antimetastatic and cytotoxic effects of 1-p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt, (±)-1,2-di (3,5-dioxopiperazin-1-yl)propane, and cyclophosphamide in mice bearing Lewis lung carcinoma. Cancer Res 41:2524
Kolar GF (1972) Synthesis of biologically active triazenes from isolable diazonium salts. Z Naturforsch [B] 27:1183
Sava G, Giraldi T, Lassiani L, Nisi C (1982a) Metabolism and mechanism of the antileukemic action of isomeric aryldimethyltriazenes. Cancer Treat Rep 66:1751
Sava G, Giraldi T, Nisi C, Bertoli G (1982b) Prophylactic antimetastatic treatment with aryldimethyltriazenes as adjuvants to surgical tumor removal in mice bearing Lewis lung carcinoma. Cancer Treat Rep 66:115
Vaughan K, Stevens MFG (1978) Monoalkyltriazenes. Chem Soc Rev 7:377
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Colombo, T., D'Incalci, M. Comparison of the antitumor activity of DTIC and 1-p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt on murine transplantable tumors and their hematological toxicity. Cancer Chemother. Pharmacol. 13, 139–141 (1984). https://doi.org/10.1007/BF00257132
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257132